Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PPIB | P23284 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | PPIG | Q13427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057615 | 1.00 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5BCHE | |
| SCHEMBL14485271 | 0.90 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL3177417 | 0.89 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| Hydrochloric Acid SCHEMBL14485267 | 0.88 | KMT2A (0.57) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL2744319 | 0.88 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL31652901 | 0.88 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5BCHE | |
| SCHEMBL15948331 | 0.87 | KMT2A (0.53) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL118108 | 0.86 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL525564 | 0.86 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5OPRD1 | |
| SCHEMBL30640436 | 0.86 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | PFIZER, INC. (US) | 2024-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | STT3A, CLSPN, STT3B | KMT2A 3063/4885EPHX2 3031/4885FABP7 2324/4885 |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | STT3A, CLSPN, STT3B | KMT2A 3063/4885EPHX2 3031/4885FABP7 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.